Name of PI: Hubert Caron, Ph.D.
Roche Innovation Center Zurich
Roche Pharma Research & Early Development (pRED)
Company address: Wagistrasse, 10
8952 Schlieren (CH)
- Sara Colombetti, Ph.D. (firstname.lastname@example.org)
- Johannes Sam, Ph.D., Senior Scientist, Group Leader In Vivo Models & Immunopharmacodynamics, Discovery Pharmacology (johannes.sam @roche.com)
- Mario Perro, Ph.D., Principal Scientist, Group Leader Preclinical Imaging, Histology and PK Core, Discovery Pharmacology (mario. email@example.com)
The Roche Innovation Center Zurich (Roche Glycart AG) is active in the research and development of engineered therapeutic antibodies, with a focus on the fields of cancer immunotherapy and immunotherapy in general. Part of the Roche Group since 2005, it employs about 160 people.
Roche is an equal opportunity employer and strictly prohibits unlawful discrimination based upon an individual’s race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, mental/physical disability, medical condition, marital status, veteran status, or any other characteristic protected by law.